John A Orwin
CIK 1477384 · PRESIDENT & CEO · last filed 2026-06-17
John A Orwin is a PRESIDENT & CEO who has filed 93 SEC Form 4 insider transactions across 9 companies since 2010. The most recent filing, for TRAX, was dated Jun 17, 2026. Across all open-market trades the lifetime net is −$8.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $3.8M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$3.77M
9
93
-$8.30M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TRAX | Director | 16,695 | $41.85 | $698.7K | $0 | 4 | 2026-06-17 |
| ANAB | Director | 16,695 | $52.11 | $870.0K | $0 | 10 | 2026-06-17 |
| TVTX | Director | 39,375 | $55.91 | $2.20M | $0 | 6 | 2026-05-21 |
| CARGO Therapeutics, Inc. (CRGX) Delisted | Director | — | $4.47 | — | $0 | 4 | 2025-08-19 |
| Seagen Inc. (SGEN) Delisted | Director | 0 | $228.74 | $0 | $56.7K | 12 | 2023-12-15 |
| Atreca, Inc. (BCEL) Delisted | President & CEO | 100,492 | $0.15 | $15.1K | $39.6K | 8 | 2023-02-13 |
| Travere Therapeutics, Inc. (RTRX) Delisted | Director | 11,875 | — | — | $0 | 4 | 2020-05-19 |
| Relypsa Inc (RLYP) Delisted | President & CEO | 0 | — | — | -$3.61M | 12 | 2016-09-02 |
| AFFYMAX INC (AFFY) Delisted | CEO | 108,000 | — | — | -$4.78M | 18 | 2013-02-05 |
Recent Filings
93 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-17 | TRAX | Exer (M) | +6,030 | $0 | EDGAR |
| 2026-06-17 | ANAB | Exer (M) | +6,030 | $0 | EDGAR |
| 2026-06-12 | TRAX | Grant (A) | — | $0 | EDGAR |
| 2026-05-21 | TVTX | Grant (A) | +4,000 | $0 | EDGAR |
| 2026-05-14 | TRAX | Grant (A) | — | $0 | EDGAR |
| 2026-04-22 | ANAB | Mixed | — | $0 | EDGAR |
| 2026-04-22 | TRAX | Grant (A) | — | $0 | EDGAR |
| 2026-01-08 | ANAB | Grant (A) | — | $0 | EDGAR |
| 2025-09-17 | ANAB | Exer (M) | +1,300 | $0 | EDGAR |
| 2025-08-19 | CARGO Therapeutics, Inc. (CRGX) Delisted | Disp (D) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.